Xianwei Ophthalmic Microsurgical Robot
Developed by Xianwei Medical, the Ophthalmic Microsurgical Robot represents a third-generation platform designed to overcome the precision limitations of human hands during delicate intraocular procedures. The system integrates master-slave dual-arm control with micrometer-level positioning and millinewton-scale force feedback, targeting vitreoretinal surgeries where natural hand tremor significantly constrains surgical outcomes.
Product Overview
Intraocular surgery demands exceptional precision—retinal vessels measure fractions of a millimeter, and procedural forces must remain below tissue damage thresholds. Even skilled surgeons experience physiological hand tremor of 50-100 micrometers, creating fundamental limitations for procedures like retinal vessel cannulation or subretinal injections.
The Xianwei Ophthalmic Microsurgical Robot addresses these constraints through robotic motion scaling and tremor filtering, translating surgeon hand movements into controlled instrument motions at ratios up to 200:1. The system provides real-time force feedback, enabling surgeons to perceive tissue interactions that would otherwise remain below human tactile thresholds.
The platform emerged from over a decade of research at Beijing University of Aeronautics and Astronautics under Professor Yang Yang, whose team’s work was included in the international reference Handbook of Robotic and Image-Guided Surgery (Elsevier, 2020).
Key Features
At 0–200x motion scaling with millinewton force feedback, this third-generation ophthalmic robot lets surgeons perform retinal vessel cannulation and subretinal injections beyond normal hand-tremor limits.
Master-Slave Dual-Arm Architecture: Independent control of two surgical instruments through ergonomic master interfaces, enabling bimanual surgical techniques.
Micrometer Positioning Precision: End-effector positioning accuracy measured in micrometers, exceeding human hand stability by an order of magnitude.
Variable Motion Scaling: Adjustable scaling ratios from 0 to 200x, allowing surgeons to select precision levels appropriate to each procedural phase.
Millinewton Force Feedback: Haptic feedback system detecting and transmitting forces in the millinewton range, providing tactile awareness for tissue contact that falls below natural human perception.
Compact End Effectors: Proprietary 2.5mm diameter instrument tips designed and manufactured in-house, compatible with intraocular surgical requirements.
Safety Architecture: Multiple emergency stop mechanisms at both control system and mechanical levels, with end effector retraction capability upon anomaly detection.
Technical Specifications
At micrometer positioning accuracy and 2.5 mm end-effector diameter, Xianwei’s ophthalmic robot delivers motion scaling up to 200x with millinewton-resolution force feedback for intraocular procedures.
| Parameter | Specification |
|---|---|
| Robotic Arms | 2 (master-slave) |
| Positioning Accuracy | Micrometer level |
| Motion Scaling Range | 0–200x |
| Force Feedback Resolution | Millinewton level |
| End Effector Diameter | 2.5mm |
| Control Architecture | Teleoperation with haptic feedback |
Clinical Applications
The robot is designed for vitreoretinal procedures where precision requirements exceed typical human manual capability:
Primary Indications:
- Retinal vessel cannulation for drug delivery
- Subretinal injection procedures
- Vitrectomy assistance
- Epiretinal membrane peeling
Target Conditions:
- Age-related macular degeneration requiring subretinal therapy
- Retinal vascular occlusion
- Diabetic retinopathy complications
- Macular holes and pucker
The company has conducted animal model experiments in collaboration with ophthalmology clinical centers, validating the platform’s capability for target procedures.
Regulatory Status
| Region | Status | Date |
|---|---|---|
| China (NMPA) | Type testing and innovative device application preparation | 2024 |
| Europe (CE) | Not applied | - |
| USA (FDA) | Not applied | - |
The robot is pursuing the innovative medical device pathway with NMPA, which provides expedited review for novel technologies meeting unmet clinical needs. Clinical trial enrollment is anticipated following type testing completion.
Frequently Asked Questions
How does this robot compare to other ophthalmic surgical robots?
The Xianwei system claims micrometer-level positioning and millinewton force feedback specifications that the company states are comparable to international benchmarks. The dual-arm master-slave architecture distinguishes it from single-arm or semi-autonomous alternatives, preserving surgeon control while enhancing precision.
What training is required to operate the system?
While commercial training programs are not yet established given pre-approval status, the master-slave interface is designed to translate familiar surgical motions rather than requiring new procedural techniques. Surgeons operate through ergonomic controllers that map naturally to instrument manipulation.
When will the robot be commercially available in China?
The company has indicated that obtaining NMPA Class III medical device registration represents a near-term priority, with initial market focus on private ophthalmology hospital chains. Specific commercial launch timing depends on regulatory pathway progression.
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.